[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JO3158B1 - عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -n-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه - Google Patents

عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -n-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه

Info

Publication number
JO3158B1
JO3158B1 JOP/2011/0125A JOP20110125A JO3158B1 JO 3158 B1 JO3158 B1 JO 3158B1 JO P20110125 A JOP20110125 A JO P20110125A JO 3158 B1 JO3158 B1 JO 3158B1
Authority
JO
Jordan
Prior art keywords
amino
fluorophenoxy
methylpyridine
carboxamide
monohydrate
Prior art date
Application number
JOP/2011/0125A
Other languages
English (en)
Inventor
Wichmann Saskia
Heilmann Werner
Gottfried Michael
Lögers Michael
Rehse Joachim
Stiehl Juergen
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3158(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of JO3158B1 publication Critical patent/JO3158B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Containers And Plastic Fillers For Packaging (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

يتعلق الاختراع الحالي بعملية (process) لتحضير: 4-{4-[({[4-chloro-3-(trifluoromethyl)¬phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, أملاحه وmonohydrate منه.
JOP/2011/0125A 2010-04-15 2011-04-13 عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -n-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه JO3158B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15

Publications (1)

Publication Number Publication Date
JO3158B1 true JO3158B1 (ar) 2017-09-20

Family

ID=44070712

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0125A JO3158B1 (ar) 2010-04-15 2011-04-13 عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -n-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه

Country Status (39)

Country Link
US (5) US8748622B2 (ar)
EP (1) EP2558448B1 (ar)
JP (1) JP5934182B2 (ar)
KR (2) KR20170129276A (ar)
CN (2) CN103980191A (ar)
AR (2) AR081060A1 (ar)
AU (1) AU2011240113B2 (ar)
BR (1) BR112012026117B1 (ar)
CA (1) CA2796238C (ar)
CL (1) CL2012002840A1 (ar)
CO (1) CO6630136A2 (ar)
CR (1) CR20120526A (ar)
CU (2) CU24123B1 (ar)
DK (1) DK2558448T3 (ar)
DO (2) DOP2012000268A (ar)
EC (1) ECSP12012234A (ar)
ES (1) ES2542610T3 (ar)
GT (1) GT201200280A (ar)
HK (1) HK1200831A1 (ar)
HR (1) HRP20150885T1 (ar)
HU (1) HUE026821T2 (ar)
IL (2) IL222348B (ar)
JO (1) JO3158B1 (ar)
MA (1) MA34156B1 (ar)
MX (1) MX2012011734A (ar)
MY (2) MY162359A (ar)
NZ (1) NZ602997A (ar)
PE (2) PE20160838A1 (ar)
PL (1) PL2558448T3 (ar)
PT (1) PT2558448E (ar)
RS (1) RS54219B1 (ar)
RU (1) RU2581585C2 (ar)
SG (2) SG184172A1 (ar)
SI (1) SI2558448T1 (ar)
TN (1) TN2012000492A1 (ar)
TW (2) TWI475992B (ar)
UA (1) UA110613C2 (ar)
UY (2) UY33290A (ar)
WO (1) WO2011128261A1 (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG155996A1 (en) * 2004-09-29 2009-10-29 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
NZ561178A (en) 2005-03-07 2010-11-26 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JO3479B1 (ar) 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
AU2013322854B2 (en) 2012-09-25 2018-07-19 Bayer Ag Combination of regorafenib and acetylsalicylic acid for treating cancer
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
WO2015049698A2 (en) * 2013-10-04 2015-04-09 Hetero Research Foundation Process for regorafenib
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
WO2016005874A1 (en) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
US20190300484A1 (en) * 2016-01-18 2019-10-03 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
FI3630112T3 (fi) 2017-06-02 2024-05-02 Bayer Healthcare Llc Regorafenibin ja nivolumabin yhdistelmä syövän hoidossa
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN114315710B (zh) * 2022-01-07 2024-04-26 江苏豪森药业集团有限公司 一种制备或纯化瑞戈非尼的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2468463C (en) 2001-12-03 2013-06-18 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
SI1580188T1 (sl) 2002-02-11 2012-02-29 Bayer Healthcare Llc Aril sečnine kot kinazni inhibitorji
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
AU2004259760B9 (en) * 2003-07-23 2011-02-03 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
JP5128948B2 (ja) 2004-08-27 2013-01-23 ニッポネックス インコーポレイテッド 癌の治療のための新規な薬剤組成物
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
SG155997A1 (en) 2004-09-29 2009-10-29 Bayer Schering Pharma Ag Process for the preparation of 4-{4-[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n- methylpyridine-2-carboxamide
SG155996A1 (en) 2004-09-29 2009-10-29 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
NZ561178A (en) 2005-03-07 2010-11-26 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
JP2009513706A (ja) 2005-10-31 2009-04-02 バイエル ヘルスケア リミティド ライアビリティ カンパニー ソラフェニブを用いた癌の治療
EP1957069A2 (en) 2005-11-14 2008-08-20 Bayer Healthcare, LLC Treatment of cancers with acquired resistance to kit inhibitors
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2668748A1 (en) * 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
CN101679362A (zh) 2006-12-20 2010-03-24 拜尔保健公司 用于治疗癌症的 4 -{ 4 - [ ({ 3 -叔丁基 - 1 - [ 3 - (羟基甲基 )苯基 ] - 1 h -吡唑 - 5 -基} -氨基甲酰基)-氨基]-3-氟苯氧基}-n-甲基吡啶-2-甲酰氨及其前药和盐
JP5885012B2 (ja) 2007-01-19 2016-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
WO2008089388A2 (en) 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
US20110257035A1 (en) 2008-10-21 2011-10-20 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
CA2760179A1 (en) 2009-05-15 2010-11-18 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
US20130183268A1 (en) 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CN103228274A (zh) 2010-10-01 2013-07-31 拜耳知识产权有限责任公司 包含取代的n-(2-芳基氨基)芳基磺酰胺的组合
JP2014518232A (ja) 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー ソラフェニブを含有する眼科用局所医薬組成物
MX2013015287A (es) 2011-06-28 2014-03-31 Bayer Healthcare Llc Composicion farmaceutica oftalmologica topica que contiene regorafenib.
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
JO3479B1 (ar) 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب

Also Published As

Publication number Publication date
US9458107B2 (en) 2016-10-04
CU20120147A7 (es) 2013-01-30
UY33290A (es) 2011-12-01
CU20140060A7 (es) 2014-10-02
AU2011240113B2 (en) 2014-12-18
MY162359A (en) 2017-06-15
CU24123B1 (es) 2015-08-27
TWI475992B (zh) 2015-03-11
TWI539951B (zh) 2016-07-01
TW201509415A (zh) 2015-03-16
JP5934182B2 (ja) 2016-06-15
EP2558448A1 (en) 2013-02-20
RS54219B1 (en) 2015-12-31
KR20170129276A (ko) 2017-11-24
TN2012000492A1 (en) 2014-04-01
US8748622B2 (en) 2014-06-10
WO2011128261A1 (en) 2011-10-20
SG10201501221UA (en) 2015-04-29
CL2012002840A1 (es) 2013-01-18
GT201200280A (es) 2014-07-23
JP2013523851A (ja) 2013-06-17
US20190144391A1 (en) 2019-05-16
KR101800041B1 (ko) 2017-11-21
AR081060A1 (es) 2012-06-06
US20170057918A1 (en) 2017-03-02
BR112012026117A2 (pt) 2015-09-08
CN103980191A (zh) 2014-08-13
RU2012148386A (ru) 2014-05-20
CN102947271A (zh) 2013-02-27
PE20130181A1 (es) 2013-02-23
CO6630136A2 (es) 2013-03-01
PL2558448T3 (pl) 2015-10-30
IL222348A0 (en) 2012-12-31
ES2542610T3 (es) 2015-08-07
DOP2016000285A (es) 2016-11-30
UA110613C2 (uk) 2016-01-25
EP2558448B1 (en) 2015-05-20
ECSP12012234A (es) 2012-11-30
RU2581585C2 (ru) 2016-04-20
CR20120526A (es) 2013-03-11
IL253119A0 (en) 2017-08-31
BR112012026117A8 (pt) 2017-12-19
DK2558448T3 (en) 2015-08-24
US10822305B2 (en) 2020-11-03
CA2796238C (en) 2019-12-31
DOP2012000268A (es) 2012-12-15
CA2796238A1 (en) 2011-10-20
HUE026821T2 (en) 2016-07-28
NZ602997A (en) 2014-10-31
HK1200831A1 (en) 2015-08-14
TW201204356A (en) 2012-02-01
PE20160838A1 (es) 2016-09-24
HRP20150885T1 (hr) 2015-10-09
UY39590A (es) 2022-01-31
US20130116442A1 (en) 2013-05-09
MY177066A (en) 2020-09-03
SG184172A1 (en) 2012-11-29
SI2558448T1 (sl) 2015-11-30
MA34156B1 (fr) 2013-04-03
AU2011240113A1 (en) 2012-10-11
US20140221661A1 (en) 2014-08-07
BR112012026117B1 (pt) 2022-08-30
PT2558448E (pt) 2015-09-01
IL222348B (en) 2018-08-30
IL253119B (en) 2018-03-29
CN102947271B (zh) 2016-11-09
US20170334857A1 (en) 2017-11-23
AR116395A2 (es) 2021-05-05
MX2012011734A (es) 2012-12-17
KR20130061670A (ko) 2013-06-11

Similar Documents

Publication Publication Date Title
JO3158B1 (ar) عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -n-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه
MY182428A (en) Crystalline forms of a prolyl hydroxylase inhibitor
PH12015501328A1 (en) Meglumine salt of 6-flouro-3-hydroxy-2-pyrazine carboxamide
MX2013006174A (es) Preparacion que comprende insulina, nicotinamida y un aminoacido.
MX2012001722A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
HK1185615A1 (en) Process for preparing pan-cdk inhibitors of the formula (i), and intermediates in the preparation (i) pan-cdk
MY170662A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MY159691A (en) New process for the synthesis of 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
SA113340924B1 (ar) عملية جديدة لتخليق 3- (2- برومو- 4،5 - داي ميثوكسي فينيل)بروبان نيتريل، وتطبيقها في تخليق إيڤابرادين وأملاح الإضافة منه مع حمض مقبول صيدلانياً
WO2011076711A3 (en) Polymorphs of salts of 4- [4- [ [4-chloro-3- (trifluoromethyl) phenyl] carbamoylamino] phenoxy] -n-methylpyridine - 2 - carboxamide
MX2014003770A (es) Tetrahidrato de la sal de l-arginina del acido s-(-)-9-fluoro-6,7-dihidro-8-(4-hidroxipiperidin-1-il)-5-metil-1- oxo-1h,5h-benzo[i,j] quinolizin-2-carboxilico puro, y un proceso para su preparacion.
JO3083B1 (ar) عملية جديدة لتخليق إيفابرادين وأملاحه المضافة مع حمض مقبول صيدلانيا
TN2013000128A1 (en) Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation